Title:Ferroptosis Inhibitors as New Therapeutic Insights into Radiation-Induced Heart Disease
Volume: 21
Issue: 1
Author(s): Soghra Farzipour, Fatemeh Jalali, Maryam Alvandi and Zahra Shaghaghi*
Affiliation:
- Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
- Department of Nuclear Medicine and Molecular Imaging, Clinical Development Research Unit of Farshchian Heart Center, Hamadan University of Medical Sciences, Hamadan, Iran
Keywords:
Ferroptosis, radiotherapy, heart disease, radioprotective, ferrostatin-1, ferroptosis inhibitor.
Abstract: Radiation-induced heart disease (RIHD) is a significant cause of morbidity in breast
and other mediastinal cancers. The many molecular and cellular patho-mechanisms that have a
role in RIHD are not completely understood. Endothelial injury, oxidative stress, and inflammation,
as well as endoplasmic reticulum and mitochondrial damage, are considered the primary
causes of RIHD. Ferroptosis is a newly discovered type of cell death that results from irondependent
lipid peroxide accumulation. As ferroptosis plays an important role in the
pathogenesis of cardiovascular diseases, it seems that it has a significant effect on RIHD. It was
recently shown that ionizing radiation (IR) generates severe ferroptosis, which is a critical component
of Radiotherapy-mediated normal cell toxicity. These findings support the use of a ferroptosis
inhibitor to reduce RIHD. In this perspective review, we summarize the role of
ferroptosis in pathogens of cardiovascular disease and radiation toxicity, and we will introduce
ferroptosis inhibitors as a new strategy to prevent or reduce RIHD.
